Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is one of the largest biopharmaceutical companies globally, headquartered in North Chicago, Illinois. The company specializes in immunology, oncology, neuroscience, aesthetics, and eye care therapeutics, making its news coverage particularly valuable for tracking developments across multiple billion-dollar healthcare markets.
AbbVie news reflects the company diverse therapeutic focus. Immunology updates often include clinical trial results for next-generation autoimmune disease treatments, including JAK inhibitors and other novel mechanisms targeting conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These announcements can signal shifts in competitive dynamics within the autoimmune drug market.
The oncology division generates news around FDA approvals, clinical trial data, and pipeline developments for cancer therapies. AbbVie cancer portfolio includes treatments for hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma, with ongoing expansion into solid tumor indications. Drug approval timelines and efficacy data from late-stage trials represent key news catalysts.
Neuroscience news covers developments in migraine treatment and Parkinson disease therapies, including CGRP-targeting drugs and advanced delivery systems. The Allergan Aesthetics division, acquired through AbbVie purchase of Allergan, generates news around cosmetic treatment innovations, market expansion, and competitive positioning in the medical aesthetics space.
Quarterly earnings reports provide insight into segment performance across immunology, oncology, and aesthetics divisions. Strategic announcements regarding acquisitions, licensing deals, and pipeline partnerships appear regularly as AbbVie pursues external innovation to supplement internal research. Bookmark this page to track regulatory decisions, clinical milestones, and strategic moves from one of biopharma largest players.
AbbVie recently presented data from Cohort 3 of the Phase 2 REFINE study at the ASH Annual Meeting, focusing on its investigational drug navitoclax combined with ruxolitinib for JAK inhibitor-naïve myelofibrosis patients. This combination therapy showed promise in reducing bone marrow fibrosis and variant allele frequency associated with myelofibrosis. Notably, spleen volume reduction was observed in various high-risk patient subgroups, and BMF grade improvement was seen in 81% of participants. The study indicates potential disease-modifying effects, although safety assessments showed common adverse events.
AbbVie presented new data at the 64th ASH Annual Meeting on IMBRUVICA (ibrutinib) for chronic lymphocytic leukemia (CLL), focusing on the CAPTIVATE and GLOW studies. Findings showed that patients with confirmed undetectable minimal residual disease experienced high progression-free survival rates, with 95% for those continuing IMBRUVICA vs. 88% for placebo. Additionally, real-world studies indicated that IMBRUVICA treatment yielded longer time to next treatment compared to other therapies. The continued investigation of IMBRUVICA reinforces its position in CLL treatment.
AbbVie has announced a collaboration with HotSpot Therapeutics to develop the first small molecule IRF5 inhibitor for treating autoimmune diseases. The deal includes an upfront payment of $40 million and potential total payments of $295 million in milestones and royalties. This collaboration aims to enhance AbbVie's immunology pipeline, targeting conditions like systemic lupus erythematosus. HotSpot’s Smart Allostery™ platform has enabled the discovery of this novel inhibitor, marking significant progress in the treatment of poorly managed autoimmune disorders.
AbbVie (NYSE: ABBV) will present 15 abstracts showcasing its migraine treatment portfolio at the 16th European Headache Federation Congress (EHC 2022) in Vienna from December 7-10, 2022. The highlights include late-breaking data from the CaMEO-I study on neck pain and the PROGRESS Phase 3 trial results for atogepant, aimed at preventing chronic migraine in Europe. AbbVie emphasizes its commitment to addressing the challenges faced by those living with migraines, asserting its leadership in migraine research and treatment solutions.
AbbVie (NYSE: ABBV) will present at the 5th Annual Evercore ISI Virtual HealthCONx Conference on November 29, 2022, at 9:55 a.m. Central time. Key executives including Rob Michael, Jeffrey R. Stewart, Scott Reents, and Tom Hudson will participate in the session. Investors can access a live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day. AbbVie focuses on innovative medicines across various therapeutic areas, including immunology and oncology.
AbbVie announced the European Commission's approval of SKYRIZI (risankizumab) as the first IL-23 inhibitor for treating adults with moderately to severely active Crohn's disease. This approval, significant for patients with inadequate responses to other therapies, is supported by the Phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Results indicated that patients on SKYRIZI showed better clinical remission and endoscopic response rates at both 12 and 52 weeks compared to placebo. The treatment is integral to AbbVie's growing IBD portfolio, aiming to alleviate symptoms and improve patient outcomes.
AbbVie (NYSE: ABBV) will present nearly 65 abstracts, including 15 oral presentations, at the upcoming American Society of Hematology (ASH) annual congress from December 10-13, 2022. The presentations will cover 8 types of blood cancers, highlighting investigational and approved therapies such as epcoritamab and navitoclax. Data aims to showcase advancements in treating chronic lymphocytic leukemia and multiple myeloma. The company emphasizes a commitment to improving patient outcomes in blood cancers, although many therapies are still under evaluation and not yet approved.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 8:30 a.m. Central time. Key executives, including Rob Michael and Scott Reents, will participate. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines across therapeutic areas such as immunology and oncology.
AbbVie celebrated its fourth annual BOTOX® Cosmetic Day, achieving record-breaking participation and sales. The event marked the highest single treatment day in the brand's 20-year history, with over 285,000 site visitors within the first hour. Allē registrations hit a new peak, and BOGO gift cards sold out, exceeding 2021 sales by 20%. The brand experienced a 130% increase in searches for local providers. These metrics reflect heightened consumer interest and satisfaction with BOTOX® Cosmetic, which remains the only FDA-approved treatment for specific facial lines.
On November 9, 2022, AbbVie (NYSE: ABBV) announced its participation in the 4th Annual Wolfe Research Healthcare Conference scheduled for November 15, 2022, at 10:30 a.m. CT. Key executives, including Rob Michael and Jeffrey Stewart, will present virtually. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later that day. AbbVie focuses on innovative medicines in various therapeutic areas, such as immunology, oncology, and neuroscience.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
